Do Options Traders Know Something About Omnicell Stock We Don't?

Investors need to pay close attention to OMCL stock based on the movements in the options market lately.

Zacks Investment Research • 14 hours ago

Omnicell (OMCL) is a Top-Ranked Value Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Jun 10, 2026

OMCL vs. HIMS: Which Stock Is the Better Value Option?

Investors interested in Medical Info Systems stocks are likely familiar with Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • Jun 10, 2026

Omnicell: Why I'm Long Into Q2 Earnings Despite The Bookings Wobble

Omnicell is rated Buy, with Q1 results showing structural margin improvement and a 660 bps operating margin jump. Q1 revenue grew 15% Y/Y to $310M, with non-GAAP EPS of $0.55 beating guidance by 53% and free cash flow tripling to $39M. Management raised FY 2026 EBITDA guidance, expects margin expansion to outpace revenue growth, and continues share repurchases.

Seeking Alpha • Jun 9, 2026

Omnicell, Inc. (OMCL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Omnicell, Inc. (OMCL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 9, 2026

Omnicell Selects Dan Mandoli to Lead Specialty Pharmacy Services Business

FORTH WORTH, Texas--(BUSINESS WIRE)--Omnicell Selects Dan Mandoli to Lead Specialty Pharmacy Services Business.

Business Wire • Jun 8, 2026

Omnicell (OMCL) is a Top-Ranked Momentum Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Jun 5, 2026

Wall Street Analysts Predict a 40.57% Upside in Omnicell (OMCL): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 40.6% in Omnicell (OMCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • Jun 5, 2026

Top Robotics Stocks Worth Investing in the Second Half of 2026

Robotics stocks like ABB gain traction as 2026 marks a surge in AI-driven automation, new cobots and strategic deals shaping the sector's next growth wave.

Zacks Investment Research • Jun 5, 2026

Omnicell (OMCL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Omnicell (OMCL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Investment Research • Jun 4, 2026